Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine versus pregabalin for neuropathic cancer pain
ACTRN12620000656932Phase 3Terminated
- Sponsor
- University of Technology Sydney
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neuralgia and cancer comparing Duloxetine with Pregabalin (2 arms). Primary endpoint: Clinically meaningful difference in worst pain intensity. Started Nov 2022; status: terminated.
02
Drugs
duloxetinepregabalin
03
Conditions
Neuralgiacancer
Beyond the preview
Go deeper on ACTRN12620000656932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000656932.